The US Food and Drug Administration (FDA) has published a warning letter addressed to the blood-pressure-tracking and wrist-wearable company Whoop, alleging it is marketing its new blood pressure feature without first getting proper approvals.
The FDA said Whoop’s Blood Pressure Insights (BPI) feature is intended to diagnose,